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Abstract
Neurological manifestations of COVID-19 have been described in both single case reports and retrospective scanty case series.
Theymay be linked to the potential neurotropism of the SARS-COV-2 virus, as previously demonstrated for other coronaviruses.
We report here the description of a multicenter retrospective-prospective observational study promoted by the Italian Society of
Neurology (SIN), involving the Italian Neurological Departments, who will consecutively recruit patients with neurological
symptoms and/or signs, occurred at the onset or as a complication of COVID-19. Hospitalized patients will be recruited either in
neurological wards or in COVID wards; in the latter cases, they will be referred from other specialists to participant neurologists.
Outpatients with clinical signs of COVID and neurological manifestations will be also referred to participating neurologists from
primary care physicians. A comprehensive data collection, in the form of electronic case report form (eCRF), will register all
possible neurological manifestations involving central nervous systems, peripheral nerves, and muscles, together with clinical,
laboratory (including cerebrospinal fluid, if available), imaging, neurological, neurophysiological, and neuropsychological data.
A follow-up at hospital discharge (in hospitalized patients), and for all patients after 3 and 6 months, is also planned. We believe
that this study may help to intercept the full spectrum of neurological manifestations of COVID-19 and, given the large diffusion
at national level, can provide a large cohort of patients available for future more focused investigations. Similar observational
studies might also be proposed at international level to better define the neurological involvement of COVID-19.
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Introduction
In the recent outbreak of COVID-19 pandemic, emerging in
China and then exported first to Iran and Italy, particularly in
the northern Lombardy region, and thereafter to a growing
number of European countries and America, single case re-
ports of co-occurrence of neurological disorders are being
reported [1, 2]. A recent self-reported questionnaire on 59
* Carlo Ferrarese
carlo.ferrarese@unimib.it
1 Department of Medicine and Surgery and Milan Center for
Neuroscience (NeuroMI), University of Milano-Bicocca and San
Gerardo Hospital, ASST-Monza, Via Pergolesi 33, Monza, Italy
2 Istituto Auxologico Italiano, IRCCS, Department of Neurology and
Laboratory of Neuroscience - Department of Pathophysiology and
Transplantation, “Dino Ferrari” Center, Università degli Studi di
Milano, Milan, Italy
3 Clinica Neurologica III, “Centro Aldo Ravelli” per le Terapie
Neurologiche Sperimentali, Dipartimento di Scienze della Salute,
Polo Universitario San Paolo, Università degli Studi di Milano,
ASST Santi Paolo e Carlo, Milano, Italy
4 Bicocca Bioinformatics Biostatistics and Bioimaging Centre,
Department of Medicine and Surgery, University of Milano –
Bicocca, Monza, Italy
5 S.C. Neurologia e Stroke Unit ASST Grande Ospedale
Metropolitano Niguarda, Milan, Italy
6 Department of Neuroscience, Biomedicine and Movement Sciences,
University of Verona, Verona, Italy
7 Department of Neurology, ASST Spedali Civili and University of
Brescia, Brescia, Italy
8 Department of Advanced Medical and Surgical Sciences, University
of Campania “L. Vanvitelli”, Naples, Italy
Neurological Sciences
https://doi.org/10.1007/s10072-020-04450-1
COVID hospitalized patients in Milan revealed a 20% preva-
lence of olfactory and taste disorders [3]. A retrospective ob-
servational study by Mao et al. [4] collected, from 16 January
2020 to 19 February 2020, two hundred fourteen hospitalized
patients with severe COVID infection in three hospitals of
Wuhan, China. Seventy-eight (36.4%) patients had neurologic
manifestations. More severe patients were likely to have neu-
rologic symptoms, such as acute cerebrovascular diseases,
impaired consciousness, and skeletal muscle injury. At pres-
ent, this is the first and only report on detailed neurologic
manifestations of the hospitalized patients with COVID-19,
and authors observed that involvement of the nervous system
carried a poor prognosis. Therefore, they called physicians to
pay close attention to any neurologic manifestations, in addi-
tion to the symptoms of respiratory system. Furthermore, on
March 4, 2020, Beijing Ditan Hospital reported for the first
time a case of viral encephalitis and the researchers confirmed
the presence of SARS-CoV-2 in the cerebrospinal fluid by
genome sequencing [5]. Autopsy reports in some deceased
patients have revealed brain tissue edema and partial neuronal
degeneration [6]. A further series of patients has been recently
reported from Strasbourg, France: agitation and corticospinal
tract signs were reported in 69% and 67% of the patients,
respectively [7].
Indeed, SARS-CoV-2, as previously demonstrated for
other coronaviruses [8–10], may infect nervous system,
skeletal muscle, and respiratory tract, since all systems
share the same ACE-2 receptors present in respiratory
system [11]. It has been also hypothesized that the poten-
tial neuroinvasion of SARS-CoV2 is partially responsible
for the acute respiratory failure of patients with COVID-
19 [12]. Stroke patients with COVID may have a worse
prognosis, for many reasons (delays in transports to hos-
pitals and in diagnostic procedures with decreased throm-
bolytic and thrombectomy treatments, lack of intensive-
care units, proinflammatory, and prothrombotic status). In
addition, critically ill patients with severe SARS-CoV-2
infections often show elevated levels of D-dimer and se-
vere platelet reduction, which may render them prone to
acute cerebrovascular events [13].
Moreover, many neurological diseases (multiple sclerosis,
Guillain-Barré, and chronic inflammatory demyelinating
polyneuropathy [CIDP], myasthenia) have immunological
pathogenesis andmight be exacerbated or triggered by COVID.
For all these reasons, close monitoring of any possible neu-
rological manifestation at the onset, during or after COVID-
19, is mandatory for the neurologic community.
We propose here a national multicenter retrospective-
prospective study, opened to Italian neurological departments
and sponsored by the Italian Society of Neurology (SIN), to
investigate the occurrence of neurological manifestations in
patients with COVID-19. Since most infected patients, who
may also present neurological complications, are not
hospitalized, but followed by primary care physician, they will
be asked to refer such patients to participating neurologists.
Study objective
The primary aim of the study is to collect detailed information
on any neurological manifestation of COVID-19. More spe-
cifically, the aims are to gather data on the following: (1) the
appearance of neurologic symptoms and/or signs at COVID-
19 onset or during the disease course, (2) the exams performed
for the diagnosis of the neurological involvement, (3) the clin-
ical course of both the COVID-19 infection and the neurolog-
ical events, but also the occurrence of possible long-term neu-
rological complications within a 6-month period of follow-up.
Design
For this aim, we propose a multicenter observational
retrospective-prospective study, performed at national level under
the patronage of the Italian Society of Neurology. The enrolment
will be both at hospital and community levels. The neurologic
participating centers will recruit consecutive COVID-19 patients
followed directly in the neurological wards or referred from
COVID wards of the same hospital with any neurological man-
ifestation occurring at the onset, during, or after recovery from
infection. Since in Italy (as well as in many countries) most
COVID-19 patients are followed at home by primary care phy-
sicians, theywill be asked fromparticipating centers to refer them
all COVID-19 patients with possible neurologic manifestations.
The duration of the recruiting period will be 6 months, starting
from March 1, 2020, to August 31, 2020, with a mixture of
retrospective and prospective data collection, and the follow-up
period will be of 6 months (until February 28, 2021).
Participants
All participants will be aged 18 or over and will fulfil one of
the two following criteria:
1. Positive PCR test for SARS-CoV-2 RNA on nasopharyn-
geal swab and/or positive serological test and/or positive
chest CT for interstitial pneumonia due to COVID-19,
independently from clinical severity, if hospitalized, and
appearance of neurological symptoms or signs
2. Clinical picture suggestive of COVID-19 (fever above
37.5 °C, symptoms of respiratory system infection) and
appearance of neurological symptoms or signs for sub-
jects referred from primary care physician.
The prospectively included participants will provide a writ-
ten informed consent to study participation. The study has
been approved by the Ethics Committee of the Promoter
Neurol Sci
(Istituto Auxologico Italiano, IRCCS Milan; 16 April 2020)
and will be approved in all the participating centers.
Data collection
To describe any possible neurological manifestation of
COVID-19, its temporal relation with the onset of systemic
infection and its evolution in time, a comprehensive data col-
lection, has been designed that includes demographic, lifestyle
habits, comorbidities, concomitant therapies, clinical charac-
teristics, therapies and outcomes of the COVID-19 infection,
clinical, imaging, biochemical, and neurophysiological data of
the neurological manifestations of COVID-19. All data will be
securely stored in an electronic case report form (eCRF) de-
veloped with the REDCap Cloud platform. Data access will
be protected by username and password according to different
profiles, depending on the user. In particular, centers will have
access only to data relative to their own center, whereas the
data manager and the biostatisticians will have online access
to the entire database. The data coordinating center will be at
the University of Milano-Bicocca.
Sample size
No formal sample size calculation has been performed for this
study. However, we expect to recruit a minimum of 1000
hospitalized patients, considering that we hope to involve a
large number of centers in the Northern Italian regions where
the epidemic is much more spread. We cannot anticipate the
amount of non-hospitalized patients since this component will
depend on the sensibility of the primary care physicians.
Statistical analysis
Continuous variables will be described with median and inter-
quartile range (IQR), or mean and standard deviation (SD), as
appropriate, and categorical data will be reported as absolute
and relative frequencies.
The descriptive analysis will allow the clinical picture of
the COVID-19 patients involved in the study, the characteri-
zation, and quantification of the degree of their neurological
involvement at diagnosis, during the course of the disease or
in the subsequent period. The estimate of the prevalence of
neurological manifestations and the estimate of the risk of
developing them will be calculated overall and for specific
disorders, along with the corresponding 95% confidence in-
tervals (using the total of COVID-19 patients in the centers
involved in the study). Data on cases referred from primary
care physicians will be used to confirm the spectrum of neu-
rologic manifestations and will be eventually analyzed in case
data from administrative registries will be available. Analyses
will be performed with the use of SAS software (version 9.4)
and R software (version 3.6).
Monitoring of the trial
A data manager, under the supervision of the biostatistician,
will perform periodic quality checks in terms of completeness,
consistence, and coherence of data. Reports with queries
center-specific will be prepared.
Discussion
As the number of patients with COVID-19 increases world-
wide, neurological manifestations have been progressively
described mostly in preliminary reports and in retrospective
case series of patients. However, so far, no prospective study
has been designed to intercept any possible neurologic mani-
festation occurring in COVID patients, either in severe hospi-
talized patients, or in mild or asymptomatic patients who, in
Italy, are invited to stay at home. The main aim of this
retrospective-prospective observational study, therefore, is to
collect the maximum number of patients with neurologic man-
ifestations of COVID-19, to describe their temporal relation
with COVID-19 symptomatology and to follow them for up to
6 months. Indeed, neurologists need to pay close attention to
COVID-19 neurological manifestations, whichmay have con-
tributed to their demise, especially for those with severe infec-
tions. Furthermore, when seeing patients with neurological
manifestations in this pandemic period, neurologists should
consider COVID-19 infection as a possible concomitant pa-
thology, so to avoid delayed diagnosis or misdiagnosis and
prevention of transmission.
To reach this goal, due to the particularly severe pan-
demic expression in Italy and specifically in Norther Italy,
a comprehensive data collection, in the form of eCRF, has
been rapidly designed to register all possible neurological
manifestations involving central nervous systems, periph-
eral nerves and muscles, together with clinical, laboratory
(including cerebrospinal fluid, if available), imaging, neu-
rological, neurophysiological, and neuropsychological da-
ta. The eCRF we provide is quite accurate to detect also
mild neurological symptoms such as hypogeusia and
hyposmia, both seeming to be particularly represented al-
so in early stage of the disease, representing a possible
clinical screening tool to further orientate testing of pauci-
symptomatic individuals [2]. A large part of Italian pa-
tients is followed at home by primary care physicians,
for this reason, we also planned to recruit these patients,
referred by primary care physicians to participating
neurologists.
A follow-up at hospital discharge (in hospitalized patients),
and for all patients after 3 and 6 months, has been also de-
signed, to provide the first analysis on the natural history of
COVID-related neurological manifestations.
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The main goal of this study is to rapidly define the
patients suffering of nervous and muscles impairment
and further make aware the neurological community of
the different aspects of neuroCOVID-19 that need to be
fully considered for further studies. The main limitation
of the previous studies is the limited cases considered,
with biases in clinical observations and data interpreta-
tion. It would be better, at this point, to avoid collection
of data from small case series and plan multicenter
studies, to include a large number of patients on a na-
tional basis, under the auspices of the Italian Society of
Neurology (SIN). This preliminary analysis will repre-
sent a useful referral for both the neurological scientific
community and the authorities, to further dissect the
different aspects of the neuroCOVID-19, addressing fur-
ther researches in areas of specific interest. Close mon-
itoring of the neurological manifestations of COVID-19
may also provide indications for specific diagnostic and/
or therapeutic procedures of unpredictable benefit in
subsets of COVID-19 patients with various central or
peripheral neurological involvement.
We believe that this Italian multicentric observational study
will rapidly provide, using adequate eCRF, accurate information
related to the central, peripheral, and muscle involvement during
the COVID-19 pandemic in the large national population of Italy.
The study may also largely contribute in shedding light on the
pathogenesis of the neurological complications in COVID-19
that is probably complex, involving a currently unknown set of
interactions between viral properties, tissue susceptibility, and
host immune response even in the nervous system. The study
may also add in recognizing that some patients that recover from
COVID-19 may complain of lasting neurological sequelae that
may have been overlooked at the time of acute illness. Therefore,
long-term follow-up for neurological deficits may be considered
as essential in Italy and the rest of the world. Furthermore, the
gained sensitivity of the new generations of neurologists in the
residency programs will be a contributing factor in further defin-
ing the multiple neuroclinical features of COVID-19 [14].
Possible collaborations with EAN and with affiliated
European National Neurological Societies, as well as with
AAN and other Neurological Societies worldwide, are wel-
come and might reveal country or region-specific patterns of
the neurological manifestations of COVID-19.
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